Overcoming the challenges of tissue delivery for oligonucleotide therapeutics

内吞循环 寡核苷酸 内体 细胞生物学 核糖核酸 内化 生物 细胞 DNA 化学 基因 内吞作用 生物化学
作者
Tufan Gökirmak,Mehran Nikan,Svenja Wiechmann,Thazha P. Prakash,Michael Tanowitz,Punit P. Seth
出处
期刊:Trends in Pharmacological Sciences [Elsevier BV]
卷期号:42 (7): 588-604 被引量:68
标识
DOI:10.1016/j.tips.2021.04.010
摘要

Synthetic therapeutic oligonucleotides (STOs) target genes and gene products by utilizing endogenous endonucleases for the degradation of cellular RNA, RNA maturation pathways by modulating splicing, and protein translation by sterically blocking the access of ribosomal machinery to mRNA. STOs cross at least two phospholipid bilayers, plasma, and endosomal membranes, to reach their biological targets, mRNA and DNA inside cells. They enter the cell through receptor-mediated endocytic uptake and escape endosomal compartments to access the cytoplasm and/or nucleus, where they exert pharmacological effects through different antisense mechanisms. Backbone and sugar modifications improve the drug properties of STOs by increasing their metabolic stability and affinity for plasma proteins to reduce glomerular filtration and urinary excretion, thereby facilitating distribution to peripheral tissues. Subsequent interactions with cell surface proteins promotes cellular internalization by endocytic pathways. Next-generation oligonucleotide drugs are targeted therapeutics conjugated to endogenous or exogenous ligands for cell-surface receptors expressed in specific cell types or tissues. Givosiran (Givlaari®) is the first ligand conjugated STO developed by Alnylam for the treatment of adults with acute hepatic porphyria. Synthetic therapeutic oligonucleotides (STO) represent the third bonafide platform for drug discovery in the pharmaceutical industry after small molecule and protein therapeutics. So far, thirteen STOs have been approved by regulatory agencies and over one hundred of them are in different stages of clinical trials. STOs hybridize to their target RNA or DNA in cells via Watson-Crick base pairing to exert their pharmacological effects. This unique class of therapeutic agents has the potential to target genes and gene products that are considered undruggable by other therapeutic platforms. However, STOs must overcome several extracellular and intracellular obstacles to interact with their biological RNA targets inside cells. These obstacles include degradation by extracellular nucleases, scavenging by the reticuloendothelial system, filtration by the kidney, traversing the capillary endothelium to access the tissue interstitium, cell-surface receptor-mediated endocytic uptake, and escape from endolysosomal compartments to access the nuclear and/or cytoplasmic compartments where their targets reside. In this review, we present the recent advances in this field with a specific focus on antisense oligonucleotides (ASOs) and siRNA therapeutics. Synthetic therapeutic oligonucleotides (STO) represent the third bonafide platform for drug discovery in the pharmaceutical industry after small molecule and protein therapeutics. So far, thirteen STOs have been approved by regulatory agencies and over one hundred of them are in different stages of clinical trials. STOs hybridize to their target RNA or DNA in cells via Watson-Crick base pairing to exert their pharmacological effects. This unique class of therapeutic agents has the potential to target genes and gene products that are considered undruggable by other therapeutic platforms. However, STOs must overcome several extracellular and intracellular obstacles to interact with their biological RNA targets inside cells. These obstacles include degradation by extracellular nucleases, scavenging by the reticuloendothelial system, filtration by the kidney, traversing the capillary endothelium to access the tissue interstitium, cell-surface receptor-mediated endocytic uptake, and escape from endolysosomal compartments to access the nuclear and/or cytoplasmic compartments where their targets reside. In this review, we present the recent advances in this field with a specific focus on antisense oligonucleotides (ASOs) and siRNA therapeutics. chemically modified, short, single-stranded oligonucleotides (typically 12–20 mer) that bind to their target RNA by Watson-Crick base-pairing principles and modulate expression of their target mRNA by multiple antisense mechanisms. routes of drug administration where the compound is directly delivered into the tissue of interest. These methods of administration bypass tissue barriers such as the blood–brain barrier (BBB) and blood–retinal barrier and reduce exposure to systemic tissues. Examples of local delivery methods include intrathecal or intraocular injections for delivery to the CNS or the eye, and aerosol delivery to the lungs. an endonuclease that specifically cleaves the RNA strand of a DNA–RNA hybrid. ASOs bind to target mRNA through complementary base pairing, recruiting RNaseH1 that leads to degradation of the target mRNA, thus preventing the translation of mRNA into protein. an siRNA or miRNA-directed endonuclease that is composed of multiprotein complex, which incorporates one strand of a siRNA or miRNA duplex for interaction with complementary mRNA sequence. Upon activation, one of the proteins in the complex (Argonaute 2), cleaves the target mRNA. double-stranded short RNA or modified duplexes that mediate targeted mRNA degradation through RISC complex formation. routes of drug administration where the compound is directly delivered into the blood stream to access tissues. Systemic delivery methods for synthetic therapeutic oligonucleotides (STO) include intravenous, intramuscular, and subcutaneous injections.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小杨完成签到,获得积分10
刚刚
清水完成签到,获得积分10
刚刚
wzx发布了新的文献求助10
刚刚
小熊维尼完成签到 ,获得积分10
刚刚
1秒前
suijinicheng发布了新的文献求助10
1秒前
1秒前
完美世界的应助被苹果亦巧采纳,获得50
1秒前
NICAI的应助被减减采纳,获得10
1秒前
adam发布了新的文献求助10
1秒前
乐观小之发布了新的文献求助10
1秒前
难过兔子完成签到,获得积分10
2秒前
2秒前
kkzbl发布了新的文献求助10
2秒前
xiaotiyang发布了新的文献求助10
2秒前
成呈发布了新的文献求助10
3秒前
zz发布了新的文献求助10
3秒前
没有回合制完成签到,获得积分20
3秒前
3秒前
soob完成签到 ,获得积分10
4秒前
kapuxinxin发布了新的文献求助10
4秒前
机灵的夜云完成签到,获得积分10
4秒前
彭于晏的应助被泡芙小姐采纳,获得10
4秒前
yang的应助被虚幻曼冬采纳,获得10
4秒前
打打的应助被泡芙小姐采纳,获得10
4秒前
4秒前
4秒前
4秒前
正直西牛完成签到,获得积分10
5秒前
跳跃煎蛋完成签到,获得积分20
5秒前
5秒前
6秒前
www完成签到,获得积分10
6秒前
刻苦耳机发布了新的文献求助10
7秒前
自觉飞飞完成签到,获得积分10
7秒前
丘比特的应助被RGG采纳,获得10
7秒前
科研通AI6.2的应助被NNi采纳,获得10
8秒前
花影移完成签到,获得积分10
8秒前
8秒前
殷勤的亦竹完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8167935
求助须知:如何正确求助?哪些是违规求助? 9560906
关于积分的说明 21758387
捐赠科研通 7759046
什么是DOI,文献DOI怎么找? 3429786
关于科研通互助平台的介绍 2553707
邀请新用户注册赠送积分活动 2474360